Multifaceted Challenges in Multisystem Atrophy Management: Medication Sensitivity, Emotional Lability, and Increased Fall Risk
Objective: Multisystem atrophy (MSA) epitomizes a formidable quandary within neurological and geriatric disciplines, delineated by complex manifestations encompassing autonomic dysfunction, parkinsonism, and cerebellar ataxia. This…Brain De-Ironization with Nasal Spray of Iron Chelator in Treatment of Multiple System Atrophy, a Case Trial
Objective: Iron removal seems to be a treatment approach in Multiple system atrophy (MSA) because pathological findings shows the accumulation of iron and α-synuclein protein…Clinical and neuroimaging factors associated with survival in Multiple System Atrophy
Objective: To assess clinical and neuroimaging factors associated with survival in a cohort of patients with a final clinical diagnosis of Multiple System Atrophy (MSA)…Plasma MicroRNA Expression Profiling in patients with Multiple System Atrophy and Parkinson’s Disease
Objective: Our objective was to identify differentially expressed, circulating miRNAs in Multiple System Atrophy-Parkinsonian type (MSA-P) and Parkinson’s disease (PD) which could serve as diagnostic…Unsupervised Learning Approach for Pathology-Based Subtyping and Staging Multiple System Atrophy
Objective: To develop a classification and staging system for multiple system atrophy (MSA) using data-driven disease progression modeling. Background: MSA exhibits varying degrees of degeneration…Movement disorders in Brain Sagging Syndrome- A Systematic Review
Objective: Objective: This study aims to systematically review the array of movement disorders observed in patients diagnosed with brain sagging syndrome (BSS) secondary to spontaneous…A 3D CNN Approach for the Classification of Multiple System Atrophy using Multimodal Multicentric MRI
Objective: To automatically distinguish between healthy controls (HC) and patients with multiple system atrophy (MSA) with a completely automatic approach using a 3D convolutional neural…Safety and Efficacy of the Anti-alpha Synuclein Monoclonal Antibody Lu AF82422 for the Treatment of Patients with MSA: Results from the Phase 2 AMULET Trial
Objective: Assess the efficacy and safety of monthly IV infusions with the anti-alpha synuclein [a-syn] monoclonal antibody Lu AF82422 for the treatment of patients with…Seed Amplification Assay for the differentiation of αSyn seed subtypes
Objective: To identify soluble αSyn-seed types present in brain homogenate (BH) and CSF using αSyn seed amplification assay (synSAA) Background: Lewy bodies and neurites are…Catalan MSA Registry (CMSAR): Applying new Clinical Criteria and Biomarkers for Increasing Diagnostic Accuracy, is New Better?
Objective: To reassess the CMSAR and determine if new criteria and new biomarkers can enhance diagnostic accuracy. Background: The CMSAR, conducted between 2015 and 2019,…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.